Report of Cholangiocarcinoma With Transheterozygous BRCA1 and BRCA2 Co-mutation.

Cholangiocarcinoma is an aggressive malignancy involving the epithelial cells of the intrahepatic, perihilar, or extrahepatic biliary tree. It is a disease that is often diagnosed late in its course and progresses quickly. Identifying genomic mutations may provide an important utility in predicting disease course and individualizing therapy for these patients.

A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC).

High-dose (HD) IL-2 is approved to treat renal cell carcinoma (RCC) with modest response rates and significant toxicity. Enhancement of cytotoxic T-cell activity by IL-2 is 1 mechanism of action. IL-2 also stimulates regulatory T lymphocytes (Tregs), which are associated with poor prognosis.

Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497.

Denileukin diftitox (DD) is approved for treatment of CD-25 expressing cutaneous T-cell lymphomas (CTCL). Initial studies of DD demonstrated responses in patients with B-cell non-Hodgkin lymphoma (NHL). This phase II trial evaluated response rate (RR) and tolerability of DD in this population.

Classical Hodgkin's lymphoma presenting with tongue involvement: a case report and review of the literature.

We report an unusual case of mixed cellularity classical Hodgkin's lymphoma with prominent involvement of the base of the tongue at diagnosis. In situ hybridization findings for Epstein-Barr virus were positive. Waldeyer's ring involvement by Hodgkin's lymphoma is uncommon with < 200 cases reported in the English literature and only 5 previous reports of Hodgkin's lymphoma involving the tongue.

Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.

Background: Doxorubicin plus ketoconazole has exhibited significant activity in patients with advanced prostate cancer. However, overall and cardiac-specific toxicity was reported to be high. Mitoxantrone has activity similar to that of doxorubicin, is less cardiotoxic, and is widely used to treat prostate cancer.

Chemotherapy dosing in the setting of liver dysfunction.

Advanced cancer in the setting of liver dysfunction poses a dilemma for physicians, as many cancer chemotherapeutic agents undergo hepatic metabolism. Most cytotoxic drugs have a narrow therapeutic index, and the administration of chemotherapy to patients with liver impairment results in complicated safety issues. We present a concise review of cancer chemotherapy dosing in the setting of liver dysfunction.

Denileukin diftitox: a concise clinical review.

Denileukin diftitox (DAB389IL-2; Ontak) is a novel recombinant fusion protein approved by the US Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma. It consists of fragments of diphtheria toxin linked to human interleukin-2 and works by targeting the high-affinity interleukin-2 receptor expressed on malignant cells. This article will review the clinical trials leading to the approval of denileukin diftitox for cutaneous T-cell lymphoma, and discuss the potential future role of this novel drug in patients with both malignant and nonmalignant diseases, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, solid tumors, psoriasis and graft-versus-host disease.

A review of recent findings involving interleukin-2-based cancer therapy.

Purpose Of Review: Highlighted in this review are the important preclinical and clinical updates of interleukin (IL)-2-based cancer immunotherapy that have been published during the last year.

Recent Findings: The review starts with a summary of the preclinical breakthroughs involving IL-2. The authors briefly examine two recent studies that take very different approaches to overcome the toxicities associated with IL-2 therapy.

Elucidation of the Wide Range of Reaction Pathways That Accompany the Electrochemical Oxidation of cis,mer-[Mn(CO)(2)(eta(1)-dpm)(eta(2)-dpm)X] (dpm = Ph(2)PCH(2)PPh(2); X = Cl, Br).

The electrochemical oxidation of cis,mer-[Mn(CO)(2)(eta(1)-dpm)(eta(2)-dpm)Br] (dpm = Ph(2)PCH(2)PPh(2)), or (cis,mer)(0),()()has been examined in dichloromethane (0.1 M Bu(4)NPF(6)) by voltammetric, bulk electrolytic, in situ and ex situ spectroelectrochemical and simulation techniques. On the voltammetric time scale at 20 degrees C, the neutral 18-electron cis,mer Mn(I) species is oxidized to the corresponding 17-electron cation which at slow scan rates isomerizes to the trans cation.